MB
RNAM

MPM BioImpact’s Avidity Biosciences RNAM Stock Holding History

MPM BioImpact’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-760,022
Closed -$33.1M – 46
2025
Q3 		$33.1M Hold
760,022
– – 5.42% 3
2025
Q2 		$21.6M Buy
760,022
+45,798
+6% +$1.37M 3.74% 7
2025
Q1 		$21.1M Buy
714,224
+11,243
+2% +$350K 3.62% 10
2024
Q4 		$20.4M Buy
702,981
+14,006
+2% +$585K 2.9% 10
2024
Q3 		$31.6M Buy
688,975
+563,975
+451% +$24.5M 4.75% 4
2024
Q2 		$5.11M Buy
+125,000
New +$3.59M 0.79% 38

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MPM BioImpact's RNAM Position: Q4 2025 in Review

MPM BioImpact sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 760,022 shares — an estimated $33.1M sold.

MPM BioImpact first reported a position in RNAM in Q2 2024 and held it in 6 quarters. The position peaked at $33.1M in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • MPM BioImpact reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • MPM BioImpact sold 760,022 Avidity Biosciences shares in Q4 2025, an estimated $33.1M.
  • MPM BioImpact first reported a position in Avidity Biosciences in Q2 2024 and held it in 6 quarters.
  • MPM BioImpact's Avidity Biosciences position peaked at $33.1M in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.